Skip to content

Patients Without Standard Modifiable Cardiovascular Risk Factors (SMuRF-less) and Their Prognosis After a ST-segment-Elevation Myocardial Infarction (STEMI)

Patients Without Standard Modifiable Cardiovascular Risk Factors (SMuRF-less) and Their Prognosis After a ST-segment-Elevation Myocardial Infarction (STEMI)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05321667
Enrollment
500
Registered
2022-04-11
Start date
2022-04-01
Completion date
2022-08-31
Last updated
2022-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STEMI

Keywords

SMuRFs, SMuRF-less, Standard Modifiable Risk Factors, Prognosis, Family History

Brief summary

The purpose of this study is to asses the prognosis of STEMI patients without standard modifiable risk factors of cardiovascular disease (diabetes mellitus, hyperlipidemia, hypertension and cigarette smoking) compare to patients presenting at least one of these risk factors.

Interventions

None listed

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

STEMI patients who had a percutaneous coronary intervention (PCI) in our PCI center.

Exclusion criteria

Pain duration exceeding 24h. Perioperative STEMI, including STEMI related to cardiac surgery.

Design outcomes

Primary

MeasureTime frameDescription
MACE (Major Adverse Cardiovascular Event)3 yearsComposite outcome including cardiovascular death or incidence of acute coronary syndrome, ischemic stroke or heart failure.

Secondary

MeasureTime frameDescription
All-cause mortality3 years
Number of patients presenting cardiovascular death during the follow-up3 yearsNumber of patients presenting death due to fatal myocardial infarction, fatal ischemic stroke, sudden death, severe heart failure and cardiogenic shock during the follow-up.
Number of patients presenting heart failure during the follow-up3 yearsNumber of patients hospitalized for acute heart failure during the follow-up, as well as patients presenting persistent symptoms of chronic heart failure after their STEMI (dyspnea NYHA \> 1) and/or long-terme need for diuretics.
Number of patients presenting ischemic stroke during the follow-up3 yearsNumber of patients presenting fatal or non fatal ischemic stroke during the follow-up

Countries

France

Contacts

Primary ContactLucas SALVATI
lu.k.salvati@gmail.com+33620607540
Backup ContactBatric POPOVIC
b.popovic@chru-nancy.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026